Syndax Pharmaceuticals (NASDAQ:SNDX) Receives New Coverage from Analysts at StockNews.com
StockNews.com started coverage on shares of Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) in a research report sent to investors on Thursday. The firm issued a sell rating on the stock. A number of other research firms have also commented on SNDX. B. Riley raised their price objective on shares of Syndax Pharmaceuticals from $34.00 to […]